Blog Case Study

63 Runs and No Convergence: When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…

Stephen DuffullJune 23, 2026

Poster

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Learn how Certara's IO Simulator was used to predict efficacy, cytokine release syndrome risk, and…

CertaraJune 23, 2026

Poster

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Discover how Quantitative Systems Pharmacology (QSP) was used to predict cytokine release syndrome risk and…

CertaraJune 23, 2026

Poster

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…

CertaraJune 22, 2026

Poster

Machine Learning based drug renal clearance predictor development and application

A machine learning QSAR model predicts human renal clearance from simple, easy-to-obtain inputs and sharpens…

CertaraJune 22, 2026

Poster

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Discover how active learning and Bayesian optimization improve virtual population generation for quantitative systems pharmacology…

CertaraJune 18, 2026

On-Demand Webinar

Building IND-Ready and Investor-Ready Development Programs

Learn how emerging biotechs can build IND-ready, investor-ready development programs using Totality of Evidence, NAMs,…

CertaraJune 15, 2026

Poster

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…

CertaraJune 9, 2026

Poster

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.

CertaraJune 9, 2026

Blog

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…

CertaraJune 9, 2026

Clinical Pharmacology

63 Runs and No Convergence: When RsNLME Succeeded Where Other PK/PD Solutions Couldn’t

Application of IO Simulator in Immuno-Oncology Combination Therapy: A Small Cell Lung Cancer Case Study

Mechanistic Modelling of CRS in T-cell Engagers – An Application for Blinatumomab

Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling

Machine Learning based drug renal clearance predictor development and application

Accelerating QSP Virtual Population Generation Through Active Learning and Bayesian Optimization

Building IND-Ready and Investor-Ready Development Programs

Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study

Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies

Beyond Compliance: What ICH M15 Means for the Future of Drug Development

Newsletter sign up

Quick links

Solutions

Contact